Jaguar Health regains Nasdaq Bid Price compliance; monitoring until May 2027

Jaguar Health, Inc.

Formal notice from Nasdaq on May 26, 2026: Jaguar complies with Bid Price Rule (closing bid ≥$1/sh).
Panel maintains jurisdiction until Sept 1, 2026; Mandatory Panel Monitor imposed until May 26, 2027.
If bid price <$1 for 30 consecutive trading days during monitoring, no 180-day grace period; delisting possible.
CEO Lisa Conte reported Q1 2026 net revenue +816% YoY and +527% QoQ, driven by out-license with Future Pak.
Company targets NDA for crofelemer formulation in mid-2027 and seeks development/commercialization partner.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.